GVR Report cover Breast Cancer Liquid Biopsy Market Size, Share & Trends Report

Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report By Circulating Biomarkers (Circulating Tumor Cells, Circulating Cell-free DNA), By Application, By Region, And Segment Forecasts, 2022 To 2030

  • Report ID: GVR453385
  • Number of Pages: 0
  • Format: Electronic (PDF)

Breast cancer liquid biopsy market is growing as a result of the increasing prevalence of breast cancer among the population, growing awareness about early diagnosis, and treatment along with a rising preference for non-invasive procedures. For instance, according to WHO, in 2020, 2.3 million women were diagnosed with breast cancer which resulted in the death of 685,000 women globally. Moreover, liquid biopsy are been proposed as a novel method for early detection of breast cancer which further increases its adoption further propelling the growth.

Technological advancements in ongoing research on circulating biomarkers have led to the development of a lesser invasive method of detecting non-hematological cancers. Liquid biopsy is considered viable for real-time monitoring of patients in comparison with conventional tumor biopsy. Owing to continuous advancements in related areas, awareness about the clinical importance of liquid biopsy is growing. To make these technologies globally available, further interventional clinical trials are needed, along with the development of an algorithm to combine proper circulating biomarkers. Several companies are undertaking initiatives to boost the global adoption of biopsies which is contributing to growth. As per John Hopkins Medicine in June 2022, liquid biopsy can be used to detect advanced breast cancer biomarkers in 5 hours, commercialization of such tests in the upcoming years is projected to make the diagnosis of the condition easier.

North America dominated the overall market in 2021 which can be attributed to high disease prevalence, rapid technological advancements, and growing government initiatives for cancer diagnosis. The U.S. is the biggest market for liquid biopsy tests owing to a high prevalence rate of the condition in the country, there is significant usage of oncology diagnostic tests. Moreover, rapid technological advancements and recent FDA approvals for liquid biopsy tests coupled with intense competition between biotechnology companies are among the factors expected to boost market growth over the forecast period. Furthermore, major players operating in the region are focusing on collaboration and expansion to meet the escalating demand. For instance, in August 2022, Guardant and Merck KGaA collaborated to expand their precision therapeutics and focus on hard-to-treat cancer.

Breast Cancer Liquid Biopsy Market Segmentation



By Circulating Biomarkers

Circulating Tumor Cells

Circulating Cell-free DNA

Extracellular Vesicles

Other Circulating Biomarkers

By Application

Targeting Treatment

Companion Diagnostics

  • Molecular

  • Others


Major companies operating in the market include Biocept, Inc., Fluxion Biosciences, Inc., F. Hoffmann-La Roche Ltd., Sysmex Corporation, Thermo Fisher Scientific Inc. Menarini Group, NeoGenomics Laboratories, Inc., Qiagen N.V., and Myriad Genetics, Inc. These players are focusing on product launches to enhance their portfolio and to maintain its presence over the market. For instance, in April 2020, Epic Sciences, Inc. expanded its blood test product portfolio in CLIA laboratory menu with the addition of DefineMBC, for characterizing metastatic breast cancer.

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.